Icaritin Hemostatic Use for Bleeding During Thrombolytic Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current Western medicine treatments for bleeding disorders, such as those caused by thrombolytic or antithrombotic drugs, are limited in their effectiveness and often lead to serious complications like hemorrhagic transformation, and there is a need for a comprehensive treatment method that can address these issues.
Innovation Solution
The use of icaritin, a polyhydroxy flavonoid monomer component from Epimedium brevicornu, to promote platelet activation, aggregation, and coagulation, thereby preventing and treating bleeding disorders caused by platelet dysfunction, coagulation abnormalities, vessel wall abnormalities, or anticoagulation and fibrinolysis abnormalities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If thrombolytic or antithrombotic drugs are used to dissolve thrombus, then thrombus dissolution effect is improved, but hemorrhagic transformation and bleeding complications occur
Solution Approach 1:
The patent uses traditional Chinese medicine compounds (such as Salvia miltiorrhiza, Paeonia lactiflora, and other herbal ingredients) as intermediary substances to modulate the hemostatic system. These compounds act as mediators that can counterbalance the excessive anticoagulant effects of thrombolytic drugs, thereby preventing hemorrhagic transformation while preserving the therapeutic thrombus-dissolving effect.
Solution Approach 2:
The patent modifies the hemostatic parameters by introducing traditional Chinese medicine compounds that can dynamically adjust coagulation factors, platelet function, and vascular integrity. This allows the system to maintain thrombus dissolution while preventing excessive bleeding by changing the physiological parameters of hemostasis in a controlled manner.
2Ease of operation
If western medicine treats bleeding disorders from single link or single factor, then treatment simplicity is improved, but curative effect is insufficient
Solution Approach 1:
The patent employs traditional Chinese medicine compounds that possess multiple functions simultaneously: they can promote platelet activation, enhance coagulation cascade, protect vessel wall integrity, and modulate fibrinolysis. This multi-functionality allows a single treatment approach to address multiple aspects of hemostasis, achieving both simplicity and effectiveness.
Solution Approach 2:
The patent uses composite formulations containing multiple traditional Chinese medicine ingredients (such as Salvia miltiorrhiza, Paeonia lactiflora, Cinnamomum cassia, and others) that work synergistically. This composite approach combines the effects of different herbal compounds to achieve comprehensive hemostatic regulation, improving curative effect while maintaining treatment simplicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Icaritin effectively shortens thromboplastin time, promotes blood coagulation, and reduces bleeding times, significantly inhibiting hemorrhagic transformations and gastrointestinal bleeding, while maintaining thrombolytic efficacy and not affecting normal coagulation indicators.
Implementation Method 1
The icaritin has a stronger osteoporosis resisting effect than other flavonoid glycoside compounds in herba epimedii and has effects on promoting osteoblast activity and inhibiting osteoclast activity in vitro... icaritin can relieve platelet dysfunction, shorten thromboplastin time, and promote blood coagulation
Data Source
AI summary
The present disclosure provides use of icaritin in preparing a drug for preventing and treating a bleeding disorder and belongs to the field of medicine. The icaritin can relieve platelet dysfunction, shorten thromboplastin time, and promote blood coagulation, and can be used for preventing and treating the bleeding disorder, especially for treating hemorrhagic transformation after cerebral infarction, gastrointestinal bleeding caused by a thrombolytic or antithrombotic drug for cerebral infarction, or a bleeding complication of a thrombolytic or antithrombotic drug for myocardial infarction.